Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 1, 2009, Pages 75.e1-75.e10

  Bellone, Stefania ^a   Anfossi, Simone ^c   O'Brien, Timothy J ^b   Cannon, Martin J ^b   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^c   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

CA125; dendritic cells; ovarian neoplasm; peptides

Indexed keywords

CA 125 ANTIGEN; CD45 ANTIGEN; CYTOKINE; GAMMA INTERFERON; PEPTIDE;

ADVANCED CANCER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL LINE; CELL POPULATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DONOR; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LEUKOCYTE; NATURAL KILLER T CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 58049160382     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.08.014     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. DiSaia P.J., and Creasman W.T. Clinical gynecologic oncology: invasive cervical cancer. 5th ed. (1997), Mosby-Year Book, St Louis 51-106
3. Bast Jr. R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., and Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 (1981) 1331-1337
4. Bast Jr. R.C., Badgwell D., Lu Z., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 Suppl 3 (2005) 274-281
5. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14 (1996) 1545-1551
6. Wagner U., Kohler S., Reinartz S., et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7 (2001) 1154-1162
7. Reinartz S., Kohler S., Schlebusch H., et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10 (2004) 1580-1587
8. Berek J.S., Taylor P.T., Gordon A., et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22 (2004) 3507-3516
9. Gordon A.N., Schultes B.C., Gallion H., et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94 (2004) 340-351
10. Ehlen T.G., Hoskins P.J., Miller D., et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15 (2005) 1023-1034
11. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., and York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 22 (2001) 348-366
12. O'Brien T.J., Beard J.B., Underwood L.J., and Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 23 (2002) 154-169
13. Yin B.W., and Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276 (2001) 27371-27375
14. Zeh III H.J., Leder G.H., Lotze M.T., et al. Flow-cytometric determination of peptide-class I complex formation: identification of p53 peptides that bind to HLA-A2. Human Immunol 39 (1994) 79-86
15. Santin A.D., Bellone S., Ravaggi A., Pecorelli S., Cannon M.J., and Parham G.P. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 96 (2000) 422-430
16. Santin A.D., Hermonat P.L., Ravaggi A., et al. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res 7 Suppl 3 (2001) 804s-810s
17. Holloway R.W., Mehta R.S., Finkler N.J., et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87 (2002) 8-16
18. Santin A.D., Zhan F., Bellone S., et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112 (2004) 14-25
19. Bignotti E., Tassi R.A., Calza S., et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 103 (2006) 405-416
20. Tsang K.Y., Palena C., Gulley J., Arlen P., and Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 10 (2004) 2139-2149
21. Wierecky J., Mueller M., and Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55 (2006) 63-67
22. Schuler G., and Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186 (1997) 1183-1187
23. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
24. Osada T., Clay T.M., Woo C.Y., Morse M.A., and Lyerly H.K. Dendritic cell-based immunotherapy. Int Rev Immunol 25 (2006) 377-413
25. Schultes B.C., and Whiteside T.L. Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay. J Immunol Methods 279 (2003) 1-15
26. Ge Q., Rao V.P., Cho B.K., Eisen H.N., and Chen J. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/MHC epitopes and strength of their interaction with T cell receptors. Proc Natl Acad Sci U S A 98 (2001) 1728-1733
27. Valitutti S., Muller S., Dessing M., and Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183 (1996) 1917-1921
28. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213